This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

This guidance, which interprets the Agency’s regulations on bioequivalence at 21 CFR part 320, provides product-specific recommendations on, among other things, the design of bioequivalence studies to support abbreviated new drug applications (ANDAs) for the referenced drug product. FDA is publishing this guidance to further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval for generic versions of this product.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

In January 2016, FDA issued a draft product-specific guidance for industry on generic ciclesonide. We are now issuing revised draft guidance for industry that replaces the previously issued guidance.

**Active Ingredient:** Ciclesonide

**Dosage Form; Route:** Aerosol, metered; inhalation

**Strengths:**
- 0.08 mg/INH
- 0.16 mg/INH

**Recommended studies:** In vitro and in vivo studies

FDA recommends the following in vitro and in vivo studies to establish bioequivalence (BE) of the test (T) and reference (R) metered dose inhalers (MDIs) containing ciclesonide.

**In Vitro Studies**

FDA recommends that prospective applicants conduct the following in vitro studies for all strengths of the T and R products. For each strength, use at least three batches each of the T and R products, with no fewer than 10 units from each batch. FDA recommends that three primary
stability batches be also used to demonstrate in vitro BE. The three batches of T product should be manufactured from, at minimum, three different batches of drug substance(s), excipient(s), and device components. The T product should consist of the final device constituent part and final drug constituent formulation intended to be marketed.

1. Type of study: Single actuation content (SAC)
   Design: The SAC test should be performed at the beginning (B), middle (M), and end (E) lifestages\(^1\) of the product, using a flow rate of 28.3 L/min. U.S. Pharmacopoeia (USP) \(<601>\) Apparatus A or another appropriate apparatus may be used to determine the SAC using a validated assay. The number of actuations per determination should be one.

**Equivalence based on:** Population bioequivalence (PBE) analysis of SAC. Refer to the product-specific guidance for *Budesonide Inhalation Suspension* for additional information regarding PBE analysis procedures.

2. Type of study: Aerodynamic particle size distribution (APSD)
   Design: The APSD test should be performed at the B and E lifestages of the product using a flow rate of 28.3 L/min or 30 L/min. The USP \(<601>\) Apparatus 1, Apparatus 6, or another appropriate method may be used to determine APSD using a validated assay. The APSD determination of each unit should be performed with a minimum number of inhalations justified by the sensitivity of the validated assay.

   Additional comments: Drug deposition on individual sites, including the mouthpiece adapter, the induction port, each stage of the cascade impactor (CI), and the filter, is requested. Mass balance accountability should be reported based on the sum of all deposition sites. For electronic submission of the individual CI data for the T and R products, provide a table using the format in the Appendix, and send them as part of the abbreviated new drug application (ANDA) submission for BE evaluation.

**Equivalence based on:** PBE analysis of impactor-sized mass (ISM).\(^2\) The CI profiles representing drug deposition on the individual stages of the CI along with the mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD) and fine particle mass (FPM) should be submitted as supportive evidence for equivalent APSD.

3. Type of study: Spray pattern
   Design: The spray pattern test should be performed at the B lifestage of the product and at two different distances from the actuator orifice. The selected distances should be at least 3 cm apart and based on the range of 3 to 7 cm from the R actuator mouthpiece.\(^3\) Impaction (thin-layer chromatography plate impaction), non-impaction (laser light sheet technology), or other suitable method may be used to determine the spray pattern.

---

\(^1\) Based on the labeled number of actuations, the terms, B lifestage, M lifestage, and E lifestage represent the first actuation(s) following the labeled number of priming actuations, the actuation(s) corresponding to 50 percent of the labeled number of actuations, and the actuation(s) corresponding to the labeled number of actuations, respectively.

\(^2\) ISM is defined as a sum of the drug mass on all stages of the CI plus the terminal filter, but excluding the top CI stage because of its lack of a specified upper cutoff size limit.

\(^3\) The distance between the actuator orifice and point of spray pattern measurement should be the same for T and R.
Additional comments: Spray pattern should be measured quantitatively in terms of ovality ratio and area within the perimeter of the true shape (to include a high proportion, e.g., 95% of the total pattern) for the automated analysis or ovality ratio and $D_{\text{max}}$ for the manual analysis. Ovality ratio is defined as the ratio of $D_{\text{max}}$ to $D_{\text{min}}$. $D_{\text{max}}$ and $D_{\text{min}}$ are the longest and shortest diameters, respectively, that pass through the center of mass or the center of gravity, as appropriate. The number of sprays per spray pattern would preferably be one.

**Equivalence based on:** At two selected distances, (i) qualitative comparison of spray shape, and (ii) PBE analysis of ovality ratio and area within the perimeter of the true shape or ovality ratio and $D_{\text{max}}$.

4. Type of study: Plume geometry  
Design: The plume geometry test should be performed at the B lifestage of the product. The timed-sequence sound-triggered flash photography method, laser light sheet technology, or other suitable method may be used to determine the plume geometry at the appropriate post-actuation delay time.

Additional comments: Plume geometry measurements should be reported at a single delay time while the fully developed plume is still in contact with the actuator mouthpiece. Plume geometry should be measured quantitatively in terms of plume angle and width. The plume angle is based on the conical region of the plume extending from a vertex that occurs at or near the actuator mouthpiece. The plume width is measured at a distance equal to the greater of the two distances selected for characterization of the spray pattern.

**Equivalence based on:** Ratio of the geometric mean of the three batches of T to that of the three batches of R (based on log transformed data) for plume angle and width, which should fall within 90 - 111%.

5. Type of study: Priming and repriming  
Design: Priming and repriming tests should take into consideration the emitted dose (ex-actuator) of a single actuation immediately following the specified number of priming or repriming actuations specified in the R product labeling. The repriming test should be performed following storage for the specified period of non-use after initial use and/or other conditions (e.g., dropping), if the R product labeling provides such repriming information.

Additional comments: For BE evaluation, we recommend the priming and repriming tests be based on products stored in the valve upright position, with the exception of MDIs for which the R labeling recommends storage in the valve down position. The priming data can be based on the SAC data at the B lifestage.

**Equivalence based on:** PBE analysis of the emitted dose of a single actuation immediately following the specified number of priming or repriming actuations specified in the R product labeling.
Pharmacokinetic BE Study
FDA recommends that prospective applicants conduct the following PK BE study for all strengths of the T and R products.

6. Type of study: Fasting
   Design: Single-dose, two-way crossover
   Dose: Minimum number of inhalations that is sufficient to characterize a PK profile by using a sensitive analytical method
   Subjects: Adult males and non-pregnant females, general population

   Additional comments: (1) Subjects enrolled for in vivo studies should be trained in the use of the inhalation aerosols in a standard fashion, prior to each treatment session, to assure a relatively consistent inspiratory flow rate and inspiratory duration. (2) The subjects should adhere to labeling as follows: “Rinse your mouth with water and spit it out. Do not swallow.” A Bio-IND is required prior to conduct of the PK study if the dose exceeds the maximum labeled single dose.

   Analytes to measure: Ciclesonide and des-ciclesonide (active metabolite) in serum

   Equivalence based on: AUC and Cmax for des-ciclesonide. The 90% confidence intervals for the geometric mean T/R ratios of AUC and Cmax should fall within the limits of 80.00-125.00%.

Comparative Clinical Endpoint BE Study
FDA recommends that prospective applicants conduct the following comparative clinical endpoint BE study for the lowest strength of the T and R products.

7. Type of study: Comparative clinical endpoint BE study
   Design: A randomized multiple-dose, placebo-controlled, parallel group design, at minimum consisting of a 2-week run-in period followed by a 8-week treatment period of the placebo, T or R product
   Strength: 0.08 mg/INH (ciclesonide)
   Dose: 0.08 mg/INH, one inhalation twice daily

   Inclusion and exclusion criteria

   Inclusion criteria should, at minimum, include:

   a. Adult male or female subjects of non-childbearing or of childbearing potential committing to consistent and correct use of an acceptable method of birth control
b. Diagnosis of asthma as defined by the National Asthma Education and Prevention Program\(^4\) at least 12 months prior to screening

c. Pre-bronchodilator FEV\(_1\) of \(\geq 60\%\) and \(\leq 85\%\) of predicted value during the screening visit and on the first day of treatment

d. \(\geq 12\%\) and \(\geq 0.20\ L\) reversibility of FEV\(_1\) within 20 minutes following 180 mcg of albuterol inhalation (pMDI)

e. Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having had \(\leq 10\) pack-years of historical use

f. Ability to replace current short-acting \(\beta\)-agonists (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study. Subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits

g. Ability to discontinue their asthma medications (inhaled corticosteroids and long-acting \(\beta\)-agonists) from the run-in period and for the remainder of the study

h. Willingness to give their written informed consent to participate in the study

Exclusion criteria should, at minimum, include:

a. Life-threatening asthma, defined as a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma related syncopal episodes(s), or hospitalizations within the past year prior to the screening or during the run-in period

b. Significant respiratory disease other than asthma (e.g., COPD, interstitial lung disease, chronic bronchitis, emphysema)

c. Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, cardiovascular, endocrine, or other diseases that, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study

d. Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within 4 weeks prior to the screening, during the run-in period, or on the day of treatment

e. Hypersensitivity to any sympathomimetic drug (e.g., albuterol) or to any corticosteroid or any of the excipients in the study drugs or rescue medication formulation

f. Patients receiving β2-blockers, anti-arrhythmics, anti-depressants, and monoamine oxidase inhibitors within four weeks prior to the screening

g. Patients who required systemic or oral corticosteroids (for any reason) within the past 6 months prior to screening

h. Evidence or history of oral candidiasis, tuberculosis, hypercorticism, adrenal suppression, or eye problems (e.g., increased intraocular pressure, glaucoma, or cataracts)

Additional comments:

- The study may enroll all asthma patients who meet the inclusion and exclusion criteria, or may be enriched by using a subpopulation of patients predicted to respond well to the study treatment (appropriate justification should be included for the population chosen for study).

- Subjects who discontinued from the study early should be identified, and the protocol should clearly, prospectively state how missing data will be handled in the statistical analyses and provide appropriate justification for the method chosen. The protocol should also include subject retention strategies and other plans to minimize missing data. If there are missing data, adequate justification should be provided that the missing data do not lead to biased equivalence determination. Detailed information for all subjects who are discontinued from the study should be provided.

- All spirometry should be conducted in accordance with American Thoracic Society Standards.

- The study should begin with a placebo run-in period at least two weeks in duration to wash out any pre-study corticosteroids/long-acting bronchodilators and to establish FEV1 baseline values. A visit to the clinic should be scheduled at the week four of the treatment period for clinical assessment of the patient’s response to the lowest dose, and to determine if the subject can continue in the study until the end of the 8-week treatment period.

- The study protocol should include pre-specified definitions of asthma exacerbation, as well as pre-specified and appropriate escape criteria with consideration to patient safety.

- The study protocol should provide a definition of compliant subjects (e.g., used at least 75% and no more than 125% of study drug doses) and specify how compliance will be verified (e.g., by the use of subject diaries).
• To ensure study sensitivity, the T and R products should both be statistically superior to placebo (p < 0.05) with regard to the BE study endpoint.

• It is the prospective applicant’s responsibility to enroll a sufficient number of subjects for the study to demonstrate BE of the T to the R product.

• A clear list of permitted and restricted medications should be provided, including justification for use (or restriction) of certain classes of respiratory therapies, considering the current standard of care for asthma.

• The start and stop date of concomitant medication use during the study should be provided in the data set in addition to the reason for the medication use. The prospective applicant should clearly explain whether the medication was used prior to baseline visit, during the study or both.

• All adverse events (AEs) should be reported, whether or not they are considered to be related to the treatment. The report of each AE should include the date of onset, description of AE, severity, relation to study medication, action taken, outcome, and date of resolution. The information will assist FDA in determining whether the incidence and severity of adverse reactions is different between the T and R products.

BE study endpoint: FEV₁ measured in the morning prior to the dosing of inhaled medications on the last day of the 8-week treatment period.

The above primary endpoint should be baseline adjusted (change from baseline). An FEV₁ baseline is defined as the average of pre-dose FEV₁ values of at least two time points measured in the morning of the first day of an 8-week treatment period. Sampling is recommended to correspond to the same time of day as used on the last day of an 8-week treatment period.

**Equivalence based on:** T/R ratio for the primary endpoint. The 90% confidence intervals for the T/R ratios for the primary endpoint should fall within the limits of 80.00-125.00%.

**Alternative approach to the comparative clinical endpoint BE study**

A comparative clinical endpoint BE study is recommended for the lowest strength of the T ciclesonide inhalation aerosol, metered. The T product is not an aqueous-based formulation, but rather is a liquefied propellant-based formulation which rapidly volatilizes upon actuation. As such, the drug forms that reach the local sites of action in the lungs are nonvolatile residual drug particles with complex morphology due to the high relative humidity in the respiratory tract, instead of droplets containing drug in solution. Within this context and considering the existing in vitro and in vivo PK BE studies recommended in this guidance, a comparative clinical endpoint BE study between T and R products is currently the recommended tool that provides information on the equivalence in clinical effect at the local sites of action in the lungs.
However, the Office of Generic Drugs (OGD) is supportive of the development of novel BE approaches. The OGD expects that these approaches, in order to support an abbreviated new drug application (ANDA) submission, should be scientifically justified with a comprehensive, significant body of data, and evaluated as statistically meaningfully as possible; this may include in vitro, in vivo and/or in silico studies. For this particular drug product, which contains a solution-based formulation, if the T formulation is Q1 and Q2 the same as the R formulation, and if the T device is sufficiently similar to the R device with respect to critical design attributes and user interface, additional supportive data may provide a foundation to help ensure the equivalence of T and R products at the local sites of action in the lungs, and thus, could be considered as a potential alternative to the currently recommended comparative clinical endpoint BE study, in the context of the weight-of-evidence approach.

Additional supportive in vitro studies may include, but are not limited to, (i) more predictive APSD testing using representative mouth-throat models and breathing profiles, (ii) characterization of emitted aerosol sprays with respect to velocity profiles and evaporation rates, (iii) dissolution, and (iv) morphology imaging comparisons, including characterization of the full range of residual drug particle sizes. Prospective applicants may also consider the use of quantitative methods and modeling (for example, physiologically-based PK and computational fluid dynamic studies) and alternative in vivo PK BE studies.

In order to clarify the FDA’s expectations for prospective applicants early in product development, and to assist prospective applicants to submit an ANDA as complete as possible, FDA strongly encourages prospective applicants to discuss their development program for an alternative approach to BE, with the FDA via the pre-ANDA meeting pathway.

Additional Information

Formulation:
FDA recommends that the T formulation be qualitatively (Q1) and quantitatively (Q2) the same as the R formulation.

Device:
Prospective applicants should refer to FDA’s Guidance for Industry, *Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA* (January 2017), which, when finalized, will provide the Agency’s current thinking on the identification and assessment of any differences in the design of the user interface for a proposed generic drug-device combination product when compared to its RLD.

FDA recommends that prospective applicants consider the following characteristics of the R product when designing the T product:

---

5 Q1 (qualitative sameness) means that the T product uses the same inactive ingredient(s) as the R product.
6 Q2 (quantitative sameness) means that concentration of the inactive ingredient(s) used in the T product are within ±5% of those used in the R product.
• Size and shape of the R product
• Number of doses in the R product
• External operating principles and external critical design attributes of the R product
• Dose indicator/counter

Revision History:  Recommended January 2016; Revised March 2021

Unique Agency Identifier:  PSG_021658
# APPENDIX

<table>
<thead>
<tr>
<th>Variable Name</th>
<th>Variable Type</th>
<th>Content</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Name</td>
<td>Character</td>
<td>TEST or REF</td>
<td>Identifier for product</td>
</tr>
<tr>
<td>LOT Number</td>
<td>Alphanumeric/Numeric</td>
<td>Alphanumeric/Numeric</td>
<td>Identifier for product lot</td>
</tr>
<tr>
<td>UNIT Number</td>
<td>Numeric</td>
<td>Numeric values</td>
<td>Identifier for unit must be unique for each product (e.g. #1-30 for test and #31-60 for ref).</td>
</tr>
<tr>
<td>Stage 1</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S1</td>
</tr>
<tr>
<td>Stage 2</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S2</td>
</tr>
<tr>
<td>Stage 3</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S3</td>
</tr>
<tr>
<td>Stage 4</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S4</td>
</tr>
<tr>
<td>Stage 5</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S5</td>
</tr>
<tr>
<td>Stage 6</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S6</td>
</tr>
<tr>
<td>Stage 7</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S7</td>
</tr>
<tr>
<td>Stage 8 or Filter</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>S8</td>
</tr>
<tr>
<td>ISM</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>ISM</td>
</tr>
<tr>
<td>MMAD</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>MMAD</td>
</tr>
<tr>
<td>GSD</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>GSD</td>
</tr>
<tr>
<td>FPM</td>
<td>Numeric</td>
<td>Numeric Values</td>
<td>FRM</td>
</tr>
</tbody>
</table>

**Example**

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>LOT</th>
<th>Unit</th>
<th>S1</th>
<th>S2</th>
<th>S3</th>
<th>S4</th>
<th>S5</th>
<th>S6</th>
<th>S7</th>
<th>S8 or Filter</th>
<th>ISM</th>
<th>MMAD</th>
<th>GSD</th>
<th>FPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEST</td>
<td>1234</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Recommended Jan 2016; Revised Mar 2021*